alexa HMTC-NB- Hematologic Malignancies Therapy And Cardiotoxicity: New Biomarkers
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Hematology & Blood Disorders
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Adel Gouri, Aoulia Dekaken, Mohamed Chefrour, Ahmed Aimen Bentorki, Amina Yakhlef, Mehdi Beleilli and Faiza Mehiddine
ScientificTracks Abstracts: J Blood Disorders Transf
DOI: 10.4172/2155-9864.S1.006
During the two last decades, relevant improvements in the treatment of different hematologic malignancies have occurred, with a significant increase in the overall survival of patients. Increasingly aggressive chemotherapy (CT), however, has caused a comparable rise in serious adverse effects. Cardiotoxicity is a well-known and potentially serious complication of hematologic malignancies therapy that can significantly impair the patient?s quality of life and substantially increase health care costs. Recently, biochemical markers of cardiac injury, especially cardiac troponins and natriuretic peptides, have been investigated in the assessment of cancer therapy-induced cardiotoxicity. More recently, new markers of myocardial ischaemia and necrosis such as heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB) have been reported to increase after chemotherapy. However, although these markers are highly sensitive, they have relatively low cardiac specificity and available data are insufficient to propose their use in the follow-up of oncology patients. The Expert Working Group on Biomarkers of Drug-Induced Cardiac Toxicity developed the following list of characteristics of ?ideal biomarkers?, which includes specificity, sensitivity, kinetics of appearance in accessible media, robust assay, and ability to bridge between preclinical and clinical applications. Strategies to minimize cardiotoxicity during treatment are crucial to prevent severe lasting effects on health and quality of life. An interdisciplinary approach is needed to foster communication between healthcare providers, and ensure optimal patient outcomes.
Adel Gouri has completed his PharmD and Clinical Biochemistry specialization from Annaba University School of Medicine. He is the Head of Laboratory of Medical Biochemistry, Ibn Zohr Public Hospital and the Chairman of the International Board of Biochemistry, World Academy of Medical Sciences (WAMS). He is also Allied Physician/Doctoral Scientist member at the American Society of Clinical Oncology (ASCO) and member of the Working Group on Atherosclerosis and Vascular Biology, European Society of Cardiology (ESC). He has published more than 15 papers in reputed journals and has been serving as an Editor-in-Chief and Editorial Board Member of repute.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version